false 0001091596 0001091596 2022-06-23 2022-06-23
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 23, 2022
 
Nuo Therapeutics, Inc.
(Exact name of Registrant as Specified in Charter)
 
 
Delaware
000-28443
23-3011702
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)
 
8285 El Rio, Suite 190, Houston, Texas 77054
(Address of Principal Executive Offices) (Zip Code)
 
(346) 396-4770
(Registrant’s telephone number, including area code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act: None
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. 
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 
 
 
Item 8.01 Other Events.
 
On June 23, 2022, Nuo Therapeutics, Inc. (the “Company”) entered into an Exclusive Sales Agent and Services Agreement (the “Agreement”) with Pacific Medical, Inc. (“PacMed”) pursuant to which PacMed was appointed an exclusive distributor for the Company’s Aurix System product within a defined territory. The Agreement also covers any future products sold by the Company but under commercial terms to be agreed between the parties. The PacMed territory covers the states of Washington, Oregon, Idaho, Montana, Wyoming, most of California, the northern half of Nevada, plus Alaska.. The term of the Agreement extends for five (5) years subject to standard termination provisions including the failure to meet agreed sales quotas. The compensation under the Agreement consists of a commission percentage on product sales plus an annual bonus opportunity of a further percentage of product sales provided annual sales quotas are exceeded by an agreed percentage increment.
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Nuo Therapeutics, Inc.
  
       
       
 
By:  
/s/ David E. Jorden
  
   
David E. Jorden
  
   
Chief Executive and Chief Financial Officer
  
 
Date: June 28, 2022
 
 
Nuo Therapeutics (QB) (USOTC:AURX)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Nuo Therapeutics (QB) Charts.
Nuo Therapeutics (QB) (USOTC:AURX)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Nuo Therapeutics (QB) Charts.